Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
Scientific Milestone Expands Growth of Paxalisib Past Oncology and Triggers $2 Million Cost to Kazia SYDNEY, Sept. 22, 2026 /PRNewswire/ ...
